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Abstract
A 66-year-old Japanese man with pulmonary metastases of renal cell carcinoma found 8 months after
radical nephrectomy was treated with interferon-alpha and tegafur-uracil. Since it failed to achieve
tumor responses resulting in progression, he was given interferon-alpha and capecitabine. After 2
courses of combination therapy with IFN-alpha and capecitabine, significant tumor responses were
obtained; two out of four pulmonary metastatic sites disappeared completely, one site showed over
50% decrease in size, and the remaining one site did no change in size. The regimen was well
tolerated and toxicity observed was World Health Organization grade 1 anorexia. His disease status
was maintained as stable disease by the repeated treatment with interferon-alpha and capecitabine for
17 months after tumor responses were obtained. However, tumor progression was observed
thereafter. He is at present under treatment with sorafenib. This is the first case report of metastatic
renal cell carcinoma, which showed different responses to two types of 5-fluorouracil prodrugs in
combination with interferon-alpha, suggesting the biochemical modulation of capecitabine by
interferon-alpha as a possible mechanism underlying the antitumor effect of the combination of
interferon-alpha and capecitabine at the clinical setting. Present case also suggests that a combination
of tumor-selective capecitabine with interferon-alpha is a potentially useful therapeutic option in
metastatic renal cell carcinoma.
Introduction
Current standard therapy against metastatic renal cell
carcinoma (RCC) is moving from the cytokine-based
therapy to the inhibition of angiogenesis with targeted
agents. Since the latter is indeed promising but is not
curative, we need to explore the further treatment regi-
mens, which would benefit RCC patients. Cytokines, such
as interleukin-2 (IL-2) and/or interferon (IFN) produce
responses in 10-15% of patients, with occasional complete
responses reported [1]. Onthe other hand, tumor response
rates of 13% to 43% in the treatment of metastatic RCC
have been reported by immunochemotherapy consisting
of IFN-alpha and fluoropyrimidines with or without
IL-2 [2-4]. Capecitabine is an orally administered,
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5-fluorouracil (5FU) by three enzymes: carboxylesterase
mainly located in the liver, cytidine deaminase in the liver
and tumors, and thymidine phosphorylase (TP) in tumors
[5]. In clinical trials in metastatic RCC, combination of
IFN-alpha and tumor-selective capecitabine has a slightly
superior overall response rate compared with capecitabine
monotherapy: 12-24% [6,7] versus 4.8-8.7%, respectively
[8,9]. Herein, we report a case of pulmonary metastases of
RCC, which were resistant to the treatment with IFN-alpha
and tegafur-uracil (UFT) but were sensitive to the
treatment with IFN-alpha and capecitabine.
Case presentation
A 66-year-old Japanese man with right RCC (cT2N0M0)
which was detected incidentally by ultrasound of health
checkup underwent radical nephrectomy on October 2005
(Figure 1). Pathological examination revealed clear cell
carcinoma with an alveolar arrangement (pT3N0). After
the operation, he was followed up periodically without
any further treatments. On June 2006, systemic examina-
tion demonstrated four coin lesions in bilateral lungs
consistent with multiple pulmonary metastases of RCC
without any other metastatic sites as shown in Figure 2
(A, D, G, J). He received combination therapy with IL-2,
IFN-alpha (Sumiferon
TM), and UFT as reported previously
[10]. It was discontinued immediately because of the skin
toxicity due to IL-2. Then, he was given UFT at a daily dose
of 300 mg three times a day and natural IFN-alpha
(Sumiferon
TM) 3 million U intramuscularly five times a
week in a course of 3 weeks on/1 week off as the first line
treatment. However, chest computed tomography (CT)
showed progression of the disease (PD) after two courses
of the treatment. We switched 3 million U of IFN-alpha
(Sumiferon
TM) to 5 million U of natural IFN-alpha
(OIF
TM) in combination with UFT based on a case report
that metastatic RCC which did not respond to natural IFN-
alpha (Sumiferon
TM) did respond to another type of
natural IFN-alpha (OIF
TM) [11]. However, two courses of
natural IFN-alpha (OIF
TM) in combination with UFT as
the second line treatment failed to achieve tumor
responses and PD was observed again as shown in Figure
2 (B, E, H, K). Combination therapy with IFN-alpha
(OIF
TM) and UFT was discontinued. On May 2007, he
was given capecitabine at a daily dose of 2400 mg twice
a day and natural IFN-alpha (OIF
TM) 5 million U
Figure 1. Abdominal CT before radical nephrectomy.
Abdominal CT showed right hypervascular renal mass
compatible with RCC.
Figure 2. Chest CT before and after the combination therapy
with IFN-alpha and capecitabine. Pulmonary metastases were
found 8 months after radical nephrectomy (A,D,G,J).
Combination therapy with IFN-alpha and UFT failed to
achieve tumor responses and PD was observed (B,E,H,K).
Two (#1, #2) out of four pulmonary metastatic sites
disappeared completely, one site (#3) showed over 50%
decrease in size, and the remaining one site (#4) did no change
in size after 2 courses of the combination therapy with
IFN-alpha and capecitabine (C,F,I,L).
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on/1 week off as the third line treatment. After 2 courses of
the combination therapy with IFN-alpha and capecitabine,
significant tumor responses were obtained; two out of four
pulmonary metastatic sites disappeared completely, one
site showed over 50% decrease in size, and the remaining
onesitedidnochangeinsizeasshowninFigure2(C,F,I,L).
This regimen was well tolerated and toxicity observed was
World Health Organization (WHO) grade 1 anorexia
without hand-foot syndrome. His disease status was
maintained as stable disease by the repeated treatment
with IFN-alpha and capecitabine for 17 months after tumor
responses were obtained. However, tumor progression was
observed thereafter. He is at present under treatment with
sorafenib.
Discussion
Present case is unique in terms of different responses to
two types of 5FU prodrugs. Namely, pulmonary meta-
stases of RCC resistant to the treatment with IFN-alpha
and UFT were sensitive to the treatment with IFN-alpha
and capecitabine. Following possible explanations may
account for the different responses to two types of 5FU
prodrugs in combination with IFN-alpha Firstly, TP
expression in tumor tissues might be involved in the
causes of different responses to two types of 5FU prodrugs.
TP is a rate-limiting enzyme for capecitabine and involved
much in the anabolic pathway of capecitabine rather than
UFT. Ishikawa et al. [12] showed that TP expression level
in tumor tissues correlated well with the efficacy of
capecitabine but not UFT in human cancer xenograft
model, suggesting that TP expression level would be a
predictive factor for capecitabine. TP expression in RCC is
also independent prognostic factor for RCC patients and
varies among them [13-15]. Thus, we examined and
evaluated TP expression in the resected kidney of the
present case by immunohistochemistry as reported pre-
viously [14], and confirmed that it had medium to high TP
expression level (data not shown). Although TP expression
level in primary site is not always the same as that in
metastatic sites, immunohistochemistry suggests that RCC
in the present case might be sensitive to capecitabine in
terms of TP expression resulting in the significant tumor
responses to capecitabine. Secondly, biochemical modu-
lation in which a modulator combined with anti-tumor
drugs changes pharmacokinetics and results in increased
efficacy and/or reduction of toxicity would be expected in
capecitabine when administered in combination with IFN-
alpha. Transfection studies [16] showed direct evidence
that enhancement of TP expression by transfection of TP
cDNA makes RCC cell line more susceptible to capecita-
bine not only in vitro but also in vivo, suggesting that
enhancement of TP expression in tumor tissues by
modulators such as IFN-alpha would increase capecita-
bine efficacy. We examined modulatory effect of IFN-
alpha on 5FU and 5’-deoxy-5-fluorouridine (5’DFUR)
which is the metabolite in the anabolic pathway of
capecitabine with a particular focus on TP expression in
human RCC cell lines [17], and showed that IFN-alpha up-
regulates TP expression and modulates fluoropyrimidine
anabolism resulting in enhancement of the sensitivity to
5FU [17] and 5’DFUR [18] in RCC cell lines. Furthermore,
extent of enhancement of the sensitivity to 5’DFUR by
IFN-alpha was higher than that in 5FU [18]. Similar results
were reported using human colon cancer cell line COLO
201 [19]. Taken together, we believe that biochemical
modulation of capecitabine by IFN-alpha via TP might
contribute to the significant tumor responses in the
present case. Thirdly, the dose of UFT used in the present
case might be insufficient to achieve the tumor responses.
Although optimal dose of UFT in Japan ranges 300 mg to
600 mg, we employed 300 mg UFT because we experi-
enced severe side effect of leukoencephalopathy-like
symptoms in metastatic RCC patient in whom complete
response (CR) was obtained by the combination of
600 mg UFT and IFN-alpha as reported previously [20].
Akaza et al. reported that combination of 300 or 600 mg
UFT and IFN-alpha showed 3 CR cases and 2 partial
response (PR) cases in 25 cases with metastatic RCC with a
overall response rate of 20% [21]. Therefore, it cannot be
excluded that 300 mg UFT used in the present case was
insufficient to achieve the tumor responses.
Conclusion
To our knowledge, this is the first case report of metastatic
RCC which showed different responses to two types of
5FU prodrugs in combination with IFN-alpha, suggesting
the biochemical modulation of capecitabine by IFN-alpha
as a possible mechanism underlying the antitumor
effect of the combination of IFN-alpha and capecitabine
at the clinical setting. Present case also suggests that a
combination of tumor-selective capecitabine with
IFN-alpha is a potentially useful therapeutic option in
metastatic RCC.
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